Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR trial
2024-519750-36-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Dec 2024
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cRGD-ZW800-1 in laryngeal squamous cell carcinoma (LSCC) and squamous cell carcinoma of the hypopharynx, sponsored by Erasmus MC. Primary endpoints: Tumor-to-background ratio (TBR) on fluorescence imaging and Number of clear resection margins. Planned start Dec 2024; status: authorised.
02
Drugs
cRGD-ZW800-1
03
Conditions
laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on 2024-519750-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519750-36-00.